GI
OCUL icon

GAMMA Investing’s Ocular Therapeutix OCUL Stock Holding History

GAMMA Investing’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.6K Sell
1,483
-616
-29% -$5.58K ﹤0.01% 3016
2026
Q1 		$17.8K Sell
2,099
-60
-3% -$572 ﹤0.01% 2772
2025
Q4 		$26.2K Buy
2,159
+609
+39% +$7.4K ﹤0.01% 2457
2025
Q3 		$18.1K Sell
1,550
-1
-0.1% -$12 ﹤0.01% 2563
2025
Q2 		$14.4K Buy
1,551
+428
+38% +$3.35K ﹤0.01% 2630
2025
Q1 		$8.23K Buy
1,123
+1,003
+836% +$7.71K ﹤0.01% 2845
2024
Q4 		$1.02K Buy
120
+82
+216% +$800 ﹤0.01% 3419
2024
Q3 		$331 Buy
+38
New +$313 ﹤0.01% 3444

Other funds holding OCUL

PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
EOJOAM
E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
CC
Courier Capital Buffalo, New York $2B AUM 24.36% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
RZH
Relyea Zuckerberg Hanson Stamford, Connecticut $1.2B AUM 28.45% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM

GAMMA Investing's OCUL Position: Q2 2026 in Review

GAMMA Investing reduced its Ocular Therapeutix (OCUL) stake by 29% in Q2 2026, selling an estimated $5.58K and leaving 1,483 shares worth $14.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3016.

GAMMA Investing first reported a position in OCUL in Q3 2024 and has held it in 8 quarters since. The position peaked at $26.2K in Q4 2025. 22 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • GAMMA Investing held 1,483 shares of Ocular Therapeutix worth $14.6K as of Q2 2026.
  • GAMMA Investing sold 616 Ocular Therapeutix shares in Q2 2026, an estimated $5.58K.
  • Ocular Therapeutix made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3016 holding.
  • GAMMA Investing first reported a position in Ocular Therapeutix in Q3 2024 and has held it in 8 quarters since.
  • GAMMA Investing's Ocular Therapeutix position peaked at $26.2K in Q4 2025.
  • 22 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.